GENFIT

Updates to 2020 Financial Calendar

• Publication of the Universal Registration Document and Annual Report on Form 20-F are postponed until the end of May 2020
• All additional dates remain unchanged, including the Annual Shareholders Meeting, scheduled for June 11, 2020.

Lille (France); Cambridge (Massachusetts, United States) — April 29, 2020 — GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced updates to its financial calendar for 2020*. These changes are in response to the current COVID-19 pandemic and organizational adjustments GENFIT has implemented, as announced in a press release issued on March 31, 2020.

GENFIT’s efforts in coordinating its response to the COVID-19 pandemic, especially those implemented for our clinical trials, have mobilized the teams involved in the preparation of the Universal Registration Document (“URD”) and the Annual Report on Form 20-F (“Form 20-F”).  These reports, which were expected to be made available on April 30, 2020, will now be made available one month later, at the end of May 2020.

Aside from the URD and Form 20-F publication date, all other dates remain unchanged, and the 2020 financial calendar is as follows:

May 18, 2020:                             Publication of revenue and cash position as of March 31, 2020

End of May 2020:                        Universal Registration Document and Form 20-F publication

June 11, 2020:                             Annual Shareholders Meeting in Lille, FR

September 30, 2020:                   Publication of the Half Year 2020 financial statements

November 16, 2020:                    Publication of revenue and cash position as of September 30, 2020

* This calendar remains tentative, and GENFIT reserves the right to amend the aforementioned dates if necessary.

ABOUT GENFIT